Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
Anthony M. Manning reported sale of 10,000 shares of Common Stock of GLUE. The sale occurred on 05/21/2026 for aggregate proceeds of $180,100.00. The filing also lists a planned stock option exercise of 10,000 shares on 06/29/2026 with cash consideration.
Monte Rosa Therapeutics Chief Medical Officer Filip Janku reported option exercises and share sales in GLUE stock. On June 23–24, he exercised options to acquire 36,000 shares of common stock at $7.56 per share and sold a total of 41,845 shares in open-market transactions at weighted average prices of $20.2214 and $21.4227 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026. After the transactions, he directly holds 59,992 shares of Monte Rosa common stock.
Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an exercise-and-sale transaction in company stock. She exercised stock options to acquire 2,175 shares of common stock at $3.98 per share, then sold 2,175 shares in an open-market transaction at $20.00 per share.
After these transactions, she directly holds 62,371 shares of common stock and 31,298 stock options. The filing notes that the trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026.
Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson reported an option exercise and share sale in company stock. On June 23, 2026, she exercised options to acquire 3,000 shares of common stock at $6.14 per share and sold 3,000 shares at $20.00 per share in an open-market transaction.
After these transactions, she directly owned 67,845 shares of common stock and held 203,290 stock options exercisable at $6.14 per share, expiring on April 12, 2031. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026.
GLUE-related insider transactions reported. The filing shows an exercise of stock options for 30,000 common shares on 06/24/2026 executed for cash. The filing also lists prior 10b5-1 sales of 11,845 common shares on 06/23/2026 for $239,522.50.
The entries identify Morgan Stanley Smith Barney LLC as the broker and give the seller name and address. The filing is administrative disclosure of the option exercise and the pre-arranged 10b5-1 disposition.
GLUE filed a Form 144 notice indicating a proposed sale of common stock related to equity compensation. The filing lists 6,000 shares tied to an exercise of stock options dated 06/23/2026 and 5,845 shares from restricted stock units dated 01/02/2025. The schedule shows these securities are to be sold through Morgan Stanley Smith Barney LLC on the 06/23/2026 NASDAQ market.
GLUE notice of proposed sale under Rule 144 by a selling party. The filing lists proposed sales of Common shares with transaction entries dated 05/22/2026, 05/27/2026, and 06/17/2026, and a proposed sale method on 06/23/2026 described as an exercise of stock options for cash.
The record shows sale-related numeric entries including 41,344.00, 43,500.00, and 41,344.00 alongside an item labeled 40,041.75 and an identifier 84,479,418; the filing is a notice of intended resale under Rule 144 rather than an offering by the issuer.
Morgan Stanley Smith Barney LLC filed a Form 144 notice to sell 16,665 shares of Common Stock pursuant to a stock option exercise to be effected on 06/23/2026 for cash.
The excerpt also lists three sales by Edmund Dunn during April 2026: 18,683 shares on 04/16/2026 for $345,635.50, 16,687 shares on 04/13/2026 for $300,366.00, and 26,117 shares on 04/08/2026 for $450,622.72.
Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an option exercise and related share sale under a pre-arranged plan. She exercised stock options for 2,176 shares of common stock at $3.98 per share and sold 2,176 shares in an open-market transaction at $19.00 per share, all on June 17, 2026 pursuant to a Rule 10b5-1 trading plan adopted on February 19, 2026. Following these transactions, she directly owns 62,371 common shares and holds 33,473 stock options.
Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson exercised options for 3,000 shares of common stock at $6.14 per share and on the same day sold 3,000 shares at $19.00 per share in an open-market transaction. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. Following the sale, Townson directly holds 67,845 common shares, along with 206,290 stock options that remain outstanding.